SAGE Therapeutics, Inc.

SAGE Therapeutics, Inc.

SAGE Therapeutics, Inc.

Overview
Date Founded

2010

Headquarters

215 First Street,Cambridge, MA 02142

Type of Company

Public

Employees (Worldwide)

637

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at SAGE Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Chief Financial Officer & Treasurer

Senior Vice President, General Counsel, Secretary

Chief Scientific Officer

Chief Research Officer

Chief Medical Officer

Chief Business Officer

Senior Vice President, People & Organizational Strategy

Senior Vice President, Global Regulatory Affairs & Policy

Senior Vice President, Technical Operations

Board of Directors

Co-Founder at Third Rock Ventures LLC

Former Senior Vice President, Chief Financial Officer & Treasurer at Alkermes Plc

Co-Founder at Tal Medical, Inc.

President & Chief Executive Officer at Aevi Genomic Medicine, Inc.

Director, President & Chief Executive Officer at SAGE Therapeutics, Inc.

President & Chief Executive Officer at UroGen Pharma Ltd.

Chief Medical Officer at Intel Corp.

President & Chief Executive Officer at Elucida Oncology, Inc.

Venture Partner at ARCH Venture Partners

Paths to SAGE Therapeutics, Inc.
Potential Connections via
Relationship Science
You
SAGE Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Jennison Associates has expertise in a range of equity strategies across styles and market-caps, as well as fixed income strategies. The firm manages portfolios based on internal fundamental research, bottom-up security selection and a highly interactive investment process. Jennison Associates specializes in fundamental analysis, which involves attempting to gain insight into the future value of a company by studying company-specific and market-related quantitative (such as financial statements) and qualitative (such as quality of company management or products) information. Although portfolio managers ultimately make investment decisions for the portfolios they manage, they work closely with research analysts and other portfolio managers in a dynamic and continuous process of updating and debating investment ideas and company-specific convictions. They use quantitative tools to create and manage some of their customized equity portfolios and their quantitatively hedged portfolios.

Details Hidden

JCM seeks to add value versus benchmarks by actively pursuing alpha generation through their own intensive fundamental research for their fundamental investment strategies. They look for companies possessing the firm's key investment criteria through proprietary research that emphasizes contact with a company's management team, competitors, suppliers and consumers, as well as in-depth and ongoing financial modeling. Holdings are generally selected one at a time with all other factors (industry, sector, country and cash allocations) being a residual of the investment process. JCM favors businesses that their research reveals have sustainable, above-average earnings growth potential and outstanding free cash flow generation, recurring revenue, profit margins and return on invested capital for their equity strategies. To build a mosaic of information in an effort to identify macro trends and inform allocations across fixed income sectors, the firm uses fundamental credit research.

Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm's in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech's investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Recent Transactions
Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Transaction Advisors
Escrow Agent

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Clients

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$7.72B
Total Enterprise Value
$3.5B
Earnings Per Share
$-8.08
Revenue
$90.3M
Total Equity
$863M
Net Profit
$-373M
TEVNet Income
-9.37x
Debt TEV
0x
Total Debt
$0
Enterprise Value Sales
38.72x
EBITDA
$-392M
EBITDAMargin
-434.39%
Investors
Details Hidden

ARCH Venture Partners focuses on seed and early-stage investments in start-up technology companies, with a particular interest in the life sciences, the physical sciences and information technology. Their life sciences investments focus on biotechnology, pharmaceuticals, medical instrumentation and informatics. Their physical sciences investments focus on companies that are pioneering technology with a range of commercial applications in chemicals/materials, electronics/instrumentation and medical instrumentation industries. The firm's focus within the information technology sector includes electronics/hardware, information, infrastructure/software and commerce. ARCH Venture Partners invests primarily in companies located in the southwestern, Midwestern, eastern seaboard and northwestern sections of the US. The firm exits most of their investments through IPOs or private sales.

Details Hidden

FMR may use a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. They may also use general macro-economic analysis as a component of its security analysis methods. In addition to relying on public financial statement information, the firm may use extensive corporate visits and interviews with issuer management teams in conducting research. When it comes to the management of the client assets according to the investment objectives, FMR may use a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR's or its affiliates' central funds. They may also engage in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

Andrew C. & Barbara B. Taylor Distinguished Professor of Psychiatry at Washington University in St.Louis - School of Medicine

Suppliers
Washington University in St. Louis Publishing | St. Louis, MO

The mission of Washington University in St. Louis is the promotion of learning — learning by students and by faculty. Teaching, the transmission of knowledge, is central to our mission, as is research, the creation of new knowledge. Faculty — composed of scholars, scientists, artists and members of the learned professions — serve society by teaching; by adding to the store of human art, creativity, understanding, and wisdom; and by providing direct services, such as health care. The university offers more than 90 programs and almost 1,500 courses leading to bachelor's, master's and doctoral degrees in a broad spectrum of traditional and interdisciplinary fields, with additional opportunities for minor concentrations and individualized programs.

Ligand Pharmaceuticals, Inc. Medical Support Services | LA JOLLA , CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

University of California Investment Services & Portfolio Management | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Competitors
Marinus Pharmaceuticals, Inc. Pharmaceuticals - Radnor, PA

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by SAGE Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of SAGE Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and SAGE Therapeutics, Inc..